We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
Unlock the market timeline & signal feed
56 signals in the last 90 days.
The order this company entered each market — oldest to newest
11 active postings
Medical Oncology Lead
Sign up to see the full signal feed
How Ipsen's international expansion compares to its competitors
IpsenYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 IpsenYou | 22 | 0 | -4% | 53 | 24 |
Global Public Affairs & Policy Lead, Neurosciences
View postingParis, Île-de-France, France · yesterday
Filler Program Director
View postingParis, Île-de-France, France · yesterday
Local Quality Assurance Manager (QMS) Iberia
View postingBarcelona, Catalonia, Spain · 2d ago
Explore Ipsen’s 2025 Integrated Annual Report
EndedA patient’s mother walked into a procurement seminar and changed everything.Global Procurement Manager Mariam S. sources the partners, manages the budgets, and keeps the chain moving. Then a mother sat down and described what it meant that Ipsen was developing a treatment for her son's rare disease. The only one in the market.That was the moment Mariam understood exactly what her work was for. 💙Learn more about Mariam's story ➡️ https://lnkd.in/ejwZzajB ...
EndedWhen Steve’s kidney cancer returned in 2018, his focus was on his family. He faced the weight of a future that suddenly felt uncertain, worrying about the milestones he might miss with his wife and children.Kidney cancer recurrence brings a unique emotional burden that reaches far beyond the clinical setting. For families like Steve’s, every day means navigating a reality where the emotional toll is often as significant as the physical one. After finding a new treatment path, Steve is now in lon ...
EndedIpsen, a global biopharmaceutical company, has announced changes to its Executive Committee. The announcement was made in Paris, France.
Ipsen reports 11.6% sales growth at CER in Q1 2025, driven by all three therapeutic areas. The company confirms its full-year 2025 financial guidance and highlights pipeline progress.
Ipsen reports positive phase III results for Onivyde in pancreatic cancer, showing 19.5 months median overall survival in long-term survivors with metastatic pancreatic adenocarcinoma.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Ipsen's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
